|Leading policy-makers and scholars explain how market forces, deregulation, and consumer choice can work to improve health care for all Americans.||
Anthrax and Lawyers
Huber, a senior fellow at the Manhattan Institute for Policy Research, explains why pharmaceutical companies remain reluctant to invest in products to treat or prevent potential bioterror attacks.
No drug company with real assets is going to mess with licensing and liability systems that require help from both the Pentagon and the terrorists to keep our own terrifying lawyers at bay. So the cutting edge of the antibodybuilding industry goes instead to tiny biodefense contractors operating under the oversight of the huge federal bureaucracies. We replace private capital with government funding, profitdriven innovation with fixedprice government contracts and personal choice with public procurement. We stock silos in Nebraska to fight bacteria that are going to pop up unexpectedly in Yankee Stadium.
|home spotlight commentary research events news about contact links archives|